Equity Brief: Europe Sees Weak Earnings In Bag, Hence The Drag
Ken Odeluga | Jul 12, 2019 06:40
Stock market snapshot as of [11/7/2019 4:04 PM]
- The day after the Fed wafted—with Powell-comments and FOMC minutes— a confirmation that it remains highly likely to cut by 25 basis points in July, European stocks still aren’t as cheered as those in the U.S. and Asia
- Both Dow and S&P 500 opened with highly significant, albeit largely symbolic moves to the ‘psychological’ levels of 27,000 and 3,000 respectively. The jury’s out as to whether their hesitant rallies can keep the markets above those round numbers into the close. In context though, they have marked investors’ positive response to the Fed’s signal nonetheless
- As per a day ago, European markets contrast with a more mixed flavour. DAX, CAC and FTSE post anaemic gains or small losses. FTSE MIB continues its post-populism recovery, rising 0.6%. This after ECB minutes showed a strong consensus for cuts this year. Germany’s upwardly revised inflation data that lifts the euro (and a point against rate cuts) may be a bone of contention. The main drag however, remains earnings pessimism. This matches sentiment on forthcoming results Stateside, but unlike on Wall Street, there’s a sense that European large-caps may struggle to outpace even the low-ball forecasts they’ve been handed. With the broad STOXX 600 up a decent 15% for the year after last week’s 2019 high, plus with policy stimulus undefined, such sentiment may only point the market lower in the second half
Corporate News
- Illustrating Thursday’s lack of enthusiasm, Europe’s large-cap gainer was Reckitt Benckiser, rising around 2.5% near close after agreeing a $1.4bn fine. The penalty is linked to formerly owned opioid maker, Indivior. That mid-cap itself rose as much as 40%. Neither are entirely out of the woods, lawsuit-wise
- Among U.S. shares, another notable 2019 laggard, insurer United Health also took the spotlight with a 5% gain whilst select rival insurers also rallied. Pharma and biotech stocks mostly went the opposite direction. The White House has just pulled the plug on a proposed drug rebate overhaul but there’s speculation that Washington may look to target makers of high-priced drugs instead
- Retail is edging back into view in a negative way. Both GameStop (NYSE:GME) and Bed Bath & Beyond (NASDAQ:BBBY) fell hard, after a necessary plan to sell new shares and after Wall Street turned sceptical on forecasts, respectively
Get The App
Upcoming economic highlights
"Disclaimer: The information and opinions in this report are for general information use only and are not intended as an offer or solicitation with respect to the purchase or sale of any currency or CFD contract. All opinions and information contained in this report are subject to change without notice. This report has been prepared without regard to the specific investment objectives, financial situation and needs of any particular recipient.
Any references to historical price movements or levels is informational based on our analysis and we do not represent or warrant that any such movements or levels are likely to reoccur in the future. While the information contained herein was obtained from sources believed to be reliable, the author does not guarantee its accuracy or completeness, nor does the author assume any liability for any direct, indirect or consequential loss that may result from the reliance by any person upon any such information or opinions."
Original Post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.